降压药对糖尿病高血压患者生活质量的影响:一项前瞻性研究

Q2 Medicine
Perspectives in Clinical Research Pub Date : 2022-07-01 Epub Date: 2021-01-08 DOI:10.4103/picr.PICR_15_20
Raj Kumar Bhardwaj, H L Kazal, Kamlesh Kohli, Rajnish Raj, Nagma Bansal, Baltej Singh, Hobinder Arora
{"title":"降压药对糖尿病高血压患者生活质量的影响:一项前瞻性研究","authors":"Raj Kumar Bhardwaj,&nbsp;H L Kazal,&nbsp;Kamlesh Kohli,&nbsp;Rajnish Raj,&nbsp;Nagma Bansal,&nbsp;Baltej Singh,&nbsp;Hobinder Arora","doi":"10.4103/picr.PICR_15_20","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diabetes mellitus is a chronic noncommunicable disease, and hypertension (HT) is the most common comorbidity which affects their quality of life (QoL).</p><p><strong>Aim: </strong>The aim of the study was to assess the effects of antihypertensive agents (viz., amlodipine, ramipril, telmisartan, and ramipril with telmisartan) on the blood pressure (BP) and QoL.</p><p><strong>Methodology: </strong>It was an open-labeled prospective intention-to-treat study done in diabetic hypertensive patients (<i>CTRI</i>/2016/10<i>/007340</i>). Patients were randomly assigned antihypertensive agents, namely, amlodipine, ramipril, telmisartan, and a combination of ramipril with telmisartan (RT) in four groups. They were evaluated for BP, blood sugar level, and QoL at baseline and 24<sup>th</sup> week.</p><p><strong>Results: </strong>After 24 weeks of therapy, systolic BP (SBP) and diastolic BP (DBP) were significantly reduced in all groups. In amlodipine, there was a mean percentage fall of SBP by 15.85% (confidence interval [CI]: 21.38-28.13) and DBP by 11.22% (CI: 8.41-12.70); in ramipril - 14.4% (CI: 18.61-25.15) and 12.4% (CI 8.88-13.99); telmisartan - 18.4% (CI: 24.89-10.79) and 14.6% (CI 10.79-16.24); and in RT group, SBP 17.7% (CI: 23.38-29.18) and DBP 12.4% (CI: 9.05-13.02). QoL score increased by 30.56% (CI: 14.30-10.90), 30.94% (CI: 14.21-10.68), 28.07% (CI: 14.89-11.20), and 28.84% (CI: 15.49-11.77), in respective groups (<i>P</i> < 0.0001, each). However, they were nonsignificant between the study groups (<i>P</i> > 0.05).</p><p><strong>Conclusion: </strong>Amlodipine, ramipril, telmisartan, and a combination of RT are equally effective to improve BP and QoL among diabetic hypertensive patients. However, amlodipine and telmisartan lacked in dry cough and more tolerable than the ramipril and RT therapy. Henceforth, amlodipine and telmisartan are better choice to control HT among DM patients.</p>","PeriodicalId":20015,"journal":{"name":"Perspectives in Clinical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/30/PCR-13-137.PMC9345252.pdf","citationCount":"1","resultStr":"{\"title\":\"Effects of antihypertensive agents on the quality of life in diabetic hypertensive patients: A prospective study.\",\"authors\":\"Raj Kumar Bhardwaj,&nbsp;H L Kazal,&nbsp;Kamlesh Kohli,&nbsp;Rajnish Raj,&nbsp;Nagma Bansal,&nbsp;Baltej Singh,&nbsp;Hobinder Arora\",\"doi\":\"10.4103/picr.PICR_15_20\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Diabetes mellitus is a chronic noncommunicable disease, and hypertension (HT) is the most common comorbidity which affects their quality of life (QoL).</p><p><strong>Aim: </strong>The aim of the study was to assess the effects of antihypertensive agents (viz., amlodipine, ramipril, telmisartan, and ramipril with telmisartan) on the blood pressure (BP) and QoL.</p><p><strong>Methodology: </strong>It was an open-labeled prospective intention-to-treat study done in diabetic hypertensive patients (<i>CTRI</i>/2016/10<i>/007340</i>). Patients were randomly assigned antihypertensive agents, namely, amlodipine, ramipril, telmisartan, and a combination of ramipril with telmisartan (RT) in four groups. They were evaluated for BP, blood sugar level, and QoL at baseline and 24<sup>th</sup> week.</p><p><strong>Results: </strong>After 24 weeks of therapy, systolic BP (SBP) and diastolic BP (DBP) were significantly reduced in all groups. In amlodipine, there was a mean percentage fall of SBP by 15.85% (confidence interval [CI]: 21.38-28.13) and DBP by 11.22% (CI: 8.41-12.70); in ramipril - 14.4% (CI: 18.61-25.15) and 12.4% (CI 8.88-13.99); telmisartan - 18.4% (CI: 24.89-10.79) and 14.6% (CI 10.79-16.24); and in RT group, SBP 17.7% (CI: 23.38-29.18) and DBP 12.4% (CI: 9.05-13.02). QoL score increased by 30.56% (CI: 14.30-10.90), 30.94% (CI: 14.21-10.68), 28.07% (CI: 14.89-11.20), and 28.84% (CI: 15.49-11.77), in respective groups (<i>P</i> < 0.0001, each). However, they were nonsignificant between the study groups (<i>P</i> > 0.05).</p><p><strong>Conclusion: </strong>Amlodipine, ramipril, telmisartan, and a combination of RT are equally effective to improve BP and QoL among diabetic hypertensive patients. However, amlodipine and telmisartan lacked in dry cough and more tolerable than the ramipril and RT therapy. Henceforth, amlodipine and telmisartan are better choice to control HT among DM patients.</p>\",\"PeriodicalId\":20015,\"journal\":{\"name\":\"Perspectives in Clinical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/30/PCR-13-137.PMC9345252.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Perspectives in Clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/picr.PICR_15_20\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perspectives in Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/picr.PICR_15_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

背景:糖尿病是一种慢性非传染性疾病,高血压(HT)是影响其生活质量的最常见合并症。目的:本研究的目的是评估降压药(氨氯地平、雷米普利、替米沙坦、雷米沙坦联合替米沙坦)对血压和生活质量的影响。方法:这是一项在糖尿病高血压患者中进行的开放标签前瞻性意向治疗研究(CTRI/2016/10/007340)。患者随机分配抗高血压药物,即氨氯地平、雷米普利、替米沙坦和雷米普利联合替米沙坦(RT)四组。分别在基线和第24周评估血压、血糖水平和生活质量。结果:治疗24周后,各组患者收缩压(SBP)、舒张压(DBP)均明显降低。氨氯地平组收缩压平均下降15.85%(置信区间[CI]: 21.38 ~ 28.13),舒张压平均下降11.22%(置信区间[CI]: 8.41 ~ 12.70);雷米普利- 14.4% (CI: 18.61-25.15)和12.4% (CI: 8.88-13.99);替米沙坦- 18.4% (CI: 24.89-10.79)和14.6% (CI: 10.79-16.24);RT组SBP为17.7% (CI: 23.38 ~ 29.18), DBP为12.4% (CI: 9.05 ~ 13.02)。各组生活质量评分分别提高30.56% (CI: 14.30-10.90)、30.94% (CI: 14.21-10.68)、28.07% (CI: 14.89-11.20)和28.84% (CI: 15.49-11.77) (P均< 0.0001)。但各研究组间差异无统计学意义(P > 0.05)。结论:氨氯地平、雷米普利、替米沙坦及联合RT治疗对改善糖尿病高血压患者血压和生活质量均有同等效果。然而,氨氯地平和替米沙坦在干咳方面缺乏,比雷米普利和RT治疗更具耐受性。因此,氨氯地平和替米沙坦是控制糖尿病患者HT的较好选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effects of antihypertensive agents on the quality of life in diabetic hypertensive patients: A prospective study.

Background: Diabetes mellitus is a chronic noncommunicable disease, and hypertension (HT) is the most common comorbidity which affects their quality of life (QoL).

Aim: The aim of the study was to assess the effects of antihypertensive agents (viz., amlodipine, ramipril, telmisartan, and ramipril with telmisartan) on the blood pressure (BP) and QoL.

Methodology: It was an open-labeled prospective intention-to-treat study done in diabetic hypertensive patients (CTRI/2016/10/007340). Patients were randomly assigned antihypertensive agents, namely, amlodipine, ramipril, telmisartan, and a combination of ramipril with telmisartan (RT) in four groups. They were evaluated for BP, blood sugar level, and QoL at baseline and 24th week.

Results: After 24 weeks of therapy, systolic BP (SBP) and diastolic BP (DBP) were significantly reduced in all groups. In amlodipine, there was a mean percentage fall of SBP by 15.85% (confidence interval [CI]: 21.38-28.13) and DBP by 11.22% (CI: 8.41-12.70); in ramipril - 14.4% (CI: 18.61-25.15) and 12.4% (CI 8.88-13.99); telmisartan - 18.4% (CI: 24.89-10.79) and 14.6% (CI 10.79-16.24); and in RT group, SBP 17.7% (CI: 23.38-29.18) and DBP 12.4% (CI: 9.05-13.02). QoL score increased by 30.56% (CI: 14.30-10.90), 30.94% (CI: 14.21-10.68), 28.07% (CI: 14.89-11.20), and 28.84% (CI: 15.49-11.77), in respective groups (P < 0.0001, each). However, they were nonsignificant between the study groups (P > 0.05).

Conclusion: Amlodipine, ramipril, telmisartan, and a combination of RT are equally effective to improve BP and QoL among diabetic hypertensive patients. However, amlodipine and telmisartan lacked in dry cough and more tolerable than the ramipril and RT therapy. Henceforth, amlodipine and telmisartan are better choice to control HT among DM patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Perspectives in Clinical Research
Perspectives in Clinical Research Medicine-Medicine (all)
CiteScore
2.90
自引率
0.00%
发文量
41
审稿时长
36 weeks
期刊介绍: This peer review quarterly journal is positioned to build a learning clinical research community in India. This scientific journal will have a broad coverage of topics across clinical research disciplines including clinical research methodology, research ethics, clinical data management, training, data management, biostatistics, regulatory and will include original articles, reviews, news and views, perspectives, and other interesting sections. PICR will offer all clinical research stakeholders in India – academicians, ethics committees, regulators, and industry professionals -a forum for exchange of ideas, information and opinions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信